Showing results (31-40 of 315) with videos related to
Sort By:
Pageof 32
Nutrients|November 11, 2022
The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative ReviewCeleste M Lavallee, Andreina Bruno, Christopher Ma, et al.Expert Opinion on Investigational Drugs|July 31, 2018
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's diseaseChristopher Ma, Vipul Jairath, Reena Khanna, et al.Journal of Inflammation Research|February 16, 2018
Clinical utility of ustekinumab in Crohn's diseasePaulo Gustavo Kotze, Christopher Ma, Abdulelah Almutairdi, et al.Gastroenterology & Hepatology|May 4, 2022
Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel DiseaseRocio Sedano, Christopher Ma, Vipul Jairath, et al.Journal of the American Chemical Society|October 10, 2017
Designer α1,6-Fucosidase Mutants Enable Direct Core Fucosylation of Intact N-Glycopeptides and N-GlycoproteinsChao Li, Shilei Zhu, Christopher Ma, et al.BMC Genomics|September 3, 2015
An unsupervised learning approach to find ovarian cancer genes through integration of biological dataChristopher Ma, Yixin Chen, Dawn Wilkins, et al.Current Drug Targets|May 23, 2019
Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?Hang Hock Shim, Christopher Ma, Paulo Gustavo Kotze, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 22, 2021
Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related EnteropathyHisham J Akhtar, Tran M Nguyen, Christopher Ma, et al.Inflammatory Intestinal Diseases|February 28, 2022
Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?Beatriz Yuki Maruyama, Christopher Ma, Remo Panaccione, et al.Alimentary Pharmacology & Therapeutics|November 10, 2018
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximabBrian G Feagan, Gordon Lam, Christopher Ma, et al.Pageof 32